Codiak Biosciences

The leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines.

Launch date

2015

Employees

51-200 people

Market cap

Enterprise valuation

€9m (Public information from Apr 2023)

San Francisco California (HQ)

http://codiakbio.com

https://twitter.com/codiakbio https://www.linkedin.com/company/codiak-biosciences/

Date	Investors	Amount	Round
Nov 2015	ARCH Venture Partners Flagship Pioneering	$31.0m	Series A
Jan 2016	ARCH Venture Partners Flagship Pioneering Alaska Permanent Fund Yukon Partners	$61.0m	Series B
Nov 2017	Qatar Investment Authority Casdin Capital ARCH Venture Partners Alexandria Venture Investments Flagship Pioneering Sirona Capital Alaska Permanent Fund Yukon Partners EcoR1 Capital Boxer Capital	$76.5m	Series C
Oct 2020	N/A	$82.5m	IPO
Feb 2021	N/A	$66.4m	Post IPO Equity
Sep 2022*	N/A	$20.0m	Post IPO Equity
Feb 2023	N/A	N/A	Bankruptcy
Jun 2023*	Evox Therapeutics	N/A	Acquisition
Total Funding		€153m

Tech stackLearn more about the technologies and tools that this company uses.

Codiak Biosciences

Codiak Biosciences

Recent News about Codiak Biosciences

Tech stack